Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

Summary

This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• ADHD

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 to 17 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Axsome Therapeutics, Inc.

Last updated on ClinicalTrials.gov

October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites